Mosaic Immunoengineering Inc Quick Ratio (PTSC) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Mosaic Immunoengineering Inc   (PTSC)

Mosaic Immunoengineering Inc 's Quick Ratio

PTSC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0 a new company low.

Within Biotechnology & Pharmaceuticals industry 147 other companies have achieved higher Quick Ratio than Mosaic Immunoengineering Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 4293 to 4560.

Explain Quick Ratio?
How much Cash & cash equivalents PTSC´s has?
What are PTSC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PTSC Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 9.7 % 9.2 % 8.9 % 11.58 % 13.03 %
Y / Y Cash & cash equivalent Change -99.95 % -99.92 % -96.85 % 453.71 % 1335 %
Quick Ratio MRQ 0 0 0 0.01 0.01
PTSC's Total Ranking # 4560 # 4293 # 4603 # 3662 # 3746
Seq. Current Liabilities Change 2.47 % 2.44 % 1.95 % 2.5 % 2.01 %
Seq. Cash & cash equivalent Change -63.89 % -98.01 % -88.6 % -40.73 % -37.64 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 148
Healthcare Sector # 937
Overall Market # 4560


Quick Ratio Statistics
High Average Low
144.2 24.73 0
(Aug 31 2013)   (Jun 30 2026)




Financial Statements
Mosaic Immunoengineering Inc 's Current Liabilities $ 6 Millions Visit PTSC's Balance sheet
Mosaic Immunoengineering Inc 's Cash & cash equivalent $ 0 Millions Visit PTSC's Balance sheet
Source of PTSC's Sales Visit PTSC's Sales by Geography


Cumulative Mosaic Immunoengineering Inc 's Quick Ratio

PTSC's Quick Ratio for the trailling 12 Months

PTSC Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 9.82 % 10.61 % 16.56 % 23.94 % 31.61 %
Y / Y Cash & cash equivalent TTM Growth -86.37 % -57.69 % -7.72 % 24.1 % -45.53 %
Quick Ratio TTM 0 0 0.01 0.01 0.01
Total Ranking TTM # 4148 # 3259 # 3182 # 3442 # 3158
Seq. Current Liabilities TTM Growth 2.34 % 2.23 % 2.15 % 2.76 % 3.08 %
Seq. Cash & cash equivalent TTM Growth -60.15 % -49.09 % -38.91 % 10 % 23.69 %

Quick ratio ranking by company, industry and sector >> Back to PTSC Financial Strength Comparisons >> Go to Compare PTSC Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q2 2026 to $6.33 millions, cumulative Quick Ratio